Provectus Biopharmaceuticals, Inc.
PVCT
$0.07
$0.017.88%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.16% | 27.73% | -59.14% | 51.84% | -133.37% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | -77.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.93% | 5.15% | -2.94% | -75.79% | 10,515.97% |
| Change in Net Operating Assets | -101.01% | -84.02% | 482.90% | -235.49% | -55.97% |
| Cash from Operations | -3.54% | -60.56% | 52.16% | -19.89% | -61.42% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 85.85% | -1.85% | 18.68% | -17.27% | -17.29% |
| Total Debt Repaid | -154.55% | 51.42% | 14.29% | -32.95% | 18.52% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | 133.33% | -- |
| Cash from Financing | 111.37% | 5.56% | -56.22% | 36.11% | 33.76% |
| Foreign Exchange rate Adjustments | -- | -100.00% | 300.00% | 111.11% | -280.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 151.98% | -549.06% | -161.08% | 83.69% | -600.00% |